注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
4D Molecular Therapeutics Inc是一家临床阶段的基因治疗公司。该公司专注于基于腺相关病毒(AAV)载体的靶向疗法的开发。该公司的产品候选集中在各个领域,包括眼科、心脏病和肺病。 该公司的候选产品包括4D-125、4D-150、4D-110、4D-310和4D-710。4D-125用于治疗带有色素性视网膜炎GTP酶调节剂 (RPGR) 基因的X连锁色素性视网膜炎 (XLRP) 患者。4D-150是为治疗湿龄相关黄斑变性 (wet-AMD) 而开发的。4D-110用于治疗无脉络膜症。4D-310是为法布里病的全身治疗而开发的。该公司正在开发4D-710,用于治疗广泛的囊性纤维化患者,不依赖于囊性纤维化跨膜电导调节剂 (CFTR)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
John F. Milligan | 60 | 2020 | Executive Chairman |
Nancy Miller-Rich | 63 | 2020 | Independent Director |
Jacob M. Chacko | 43 | 2019 | Independent Director |
David H. Kirn | 60 | 2013 | Co-Founder, CEO & Director |
Daniel F. Takefman | 56 | 2023 | Member of Scientific Advisory Board |
Paul J. Utz | - | 2023 | Member of Scientific Advisory Board |
Amy Rosenberg | - | 2023 | Member of Scientific Advisory Board |
Ronal Crystal | - | 2023 | Member of Scientific Advisory Board |
Amit Gaggar | - | 2023 | Member of Scientific Advisory Board |
Richard B. Moss | - | 2023 | Member of Scientific Advisory Board |
Ramesh Shivdasani | - | - | Member of the Scientific Advisory Board |
Ronald G. Crystal | - | - | Member of the Scientific Advisory Board |
Douglas Hanahan | - | - | Member of the Scientific Advisory Board |
Charles P. Theuer | 60 | 2015 | Independent Director |
Shawn Cline Tomasello | 65 | 2020 | Independent Director |
Susannah Gray | 63 | 2020 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核